These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6576465)

  • 1. Latent period of 9 years in the presentation of a myeloproliferative disorder.
    Watkins SM; Williams JR; Turnbull AL
    Scand J Haematol; 1983 Sep; 31(3):280-2. PubMed ID: 6576465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daunorubicin. Results in childhood leukaemia.
    Matthews RN; Colebatch JH
    Arch Dis Child; 1972 Apr; 47(252):272-7. PubMed ID: 4502569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell kinetics in leukemia. Correlation with clinical features and response to chemotherapy.
    Vogler WR; Groth D; Garwood FA
    Arch Intern Med; 1975 Jul; 135(7):950-4. PubMed ID: 1080405
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of acute myelomonocytic leukaemia associated with myelomatosis.
    Parker AC
    Scand J Haematol; 1973; 11(4):257-60. PubMed ID: 4521505
    [No Abstract]   [Full Text] [Related]  

  • 5. Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.
    Burke PJ; Karp JE; Braine HG; Vaughan WP
    Cancer Res; 1977 Jul; 37(7 Pt 1):2138-46. PubMed ID: 266416
    [No Abstract]   [Full Text] [Related]  

  • 6. The disappearance of ring sideroblasts in myeloblastic leukaemia in remission.
    Shaw MT; Foadi M
    Scand J Haematol; 1971; 8(3):177-9. PubMed ID: 5285822
    [No Abstract]   [Full Text] [Related]  

  • 7. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin.
    Taub JW; Stout ML; Buck SA; Huang X; Vega RA; Becton DL; Ravindranath Y
    Leukemia; 1997 Sep; 11(9):1594-5. PubMed ID: 9305619
    [No Abstract]   [Full Text] [Related]  

  • 8. Serial quantitative observations of leukemic and normal hematopoietic cells in the bone marrow of acute leukemia under chemotherapy.
    Ohshima T; Amaki I
    Tohoku J Exp Med; 1976 May; 119(1):27-40. PubMed ID: 1065964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daunorubicin in the therapy of acute granulocytic leukemia.
    Weil M; Glidewell OJ; Jacquillat C; Levy R; Serpick AA; Wiernik PH; Cuttner J; Hoogstraten B; Wasserman L; Ellison RR; Gailani S; Brunner K; Silver RT; Rege VB; Cooper MR; Lowenstein L; Nissen NI; Haurani F; Blom J; Boiron M; Bernard J; Holland JF
    Cancer Res; 1973 May; 33(5):921-8. PubMed ID: 4512953
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter: Myeloblastic transformation.
    Colvin BT; Turnbull A; Jenkins G
    Br Med J; 1974 Sep; 3(5932):688. PubMed ID: 4529645
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy of acute leukemia.
    Holland JF
    Hamatol Bluttransfus; 1970; 9():58-65. PubMed ID: 5279393
    [No Abstract]   [Full Text] [Related]  

  • 12. Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
    Rosenthal NS; Farhi DC
    Am J Clin Pathol; 1991 Apr; 95(4):556-60. PubMed ID: 2014782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the mode of decrease of leukemic cells during treatment of acute leukemia.
    Masaoka T; Hasegawa Y; Ueda T; Takubo T; Shibata H
    Eur J Cancer (1965); 1976 Feb; 12(2):143-9. PubMed ID: 177291
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia.
    Carey RW; Ribas-Mundo M; Ellison RR; Glidewell O; Lee ST; Cuttner J; Levy RN; Silver R; Blom J; Haurani F; Spurr CL; Harley JB; Kyle R; Moon JH; Eagan RT; Holland JH
    Cancer; 1975 Nov; 36(5):1560-6. PubMed ID: 1059499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine.
    Lilleyman JS; Harrison JF; Black JA
    Blood; 1977 Apr; 49(4):559-62. PubMed ID: 265178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive chemotherapy of acute myelogenous leukaemia.
    Gorman A; Fennelly JJ; O'Connell LG
    J Ir Med Assoc; 1972 Oct; 65(20):509-13. PubMed ID: 4507652
    [No Abstract]   [Full Text] [Related]  

  • 17. Differentiation in myelodysplastic, myeloid leukaemic and normal haemopoietic cells: a new approach exploiting the synergistic interaction between differentiation inducers and DNA synthesis inhibitors.
    Francis GE; Guimaraes JE; Berney JJ; Wing MA
    Haematol Blood Transfus; 1985; 29():402-8. PubMed ID: 3928452
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias.
    Raza A; Ucar K; Preisler HD; Mayers G
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):9-19. PubMed ID: 3892706
    [No Abstract]   [Full Text] [Related]  

  • 19. Leukemic dermal infiltrate at the exit site of a central venous catheter.
    Martino R; Sureda A; Sitjas D; Nomdedéu J; Domingo-Albòs A
    Haematologica; 1993; 78(2):132-4. PubMed ID: 8349191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 13-years remission in chronic myelocytic leukemia after a single course of busulfan.
    Weinberger A; Benjamin D; Douer D; Barabash G; Djaldetti M; Pinkhas J
    Acta Haematol; 1978; 59(6):354-9. PubMed ID: 97894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.